Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Pfizer (PFE) are worth retaining in one's portfolio.
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on the shares of Eli Lilly And Co LLY and maintained a price target of $885.
Eli Lilly's blockbuster new weight-loss treatment is helping to drive a $130 billion anti-obesity market. Electric vehicles, self-driving taxis, and humanoid robots give Tesla's shareholders multiple ways to win.
Many top companies have announced stock splits this year after their shares surged in recent times. These operations lower the price of each individual share, making the stock more accessible for a broader range of investors.
Eli Lilly stock has soared, but investment bank analysts who follow the drugmaker think it can climb higher. According to electronic health records, Eli Lilly's drug for chronic weight management is outperforming the competition.
Researchers compared the effectiveness of Novo Nordisk and Eli Lilly's weight loss drugs. Patients stopped treatment with both at high rates.
The Food and Drug Administration recently approved Kisunla as a treatment for early symptomatic Alzheimer's disease. Despite the news, shares of Eli Lilly didn't take off.
Eli Lilly and Novo Nordisk compete in the diabetes and obesity care markets. Outside of weight loss, Lilly also has a strong portfolio of medicines used in cancer, plaque psoriasis, and more.
Eli Lilly has earned approval for an Alzheimer's disease therapy. It's yet another blockbuster drug for its lineup.
Eli Lilly (NYSE: LLY) stock has been a winner for investors of late, owing largely to strong consumer demand for obesity drugs.
Growth stocks have been in the spotlight since 1995. This year, Eli Lilly and the Vanguard Growth Index Fund ETF Shares have been top performers in the category.
Pharmaceutical stocks have not set the world on fire, with a few exceptions. Since the pandemic ended, pharma stocks have largely fallen out of favor with investors amid declining sales and mixed financial results.